Latest Distribution Agreements News

Atomo Diagnostics reports strong commercial momentum in Q4 FY25, highlighted by a major US supply agreement, rapid growth in HIV self-test sales, and promising data for its syphilis test.

Osteopore Limited reports a three-fold increase in craniofacial implant sales within a year of signing an exclusive distribution deal with Zimmer Biomet, signaling strong early traction across key global markets.

De.mem Limited has reported its second highest quarterly cash receipts ever, alongside a fourth consecutive quarter of positive operating cash flow, positioning the company for a record full-year 2025 performance.

EZZ Life Science Holdings marked a pivotal quarter with the launch of its EZZDAY brand in the US, a significant Southeast Asia distribution agreement, and expanded domestic retail presence, driving a 46% jump in customer receipts.

Compumedics has secured two significant four-year distribution agreements in China worth A$24.4 million, reinforcing its strategic foothold in Asia with committed annual growth of at least 10%.

Wide Open Agriculture reports a remarkable 243% jump in cash receipts driven by soaring lupin protein sales and secures a strategic foothold in China through an exclusive distribution deal.

icetana Limited reports its strongest quarterly annual recurring revenue growth in over four years, boosted by a landmark $3.6 million strategic partnership with SoftBank Robotics Group and expanding global deployments.

Nuchev Limited reports a record-breaking Q4 FY25 with revenues soaring 167% year-on-year, driven by strong growth across multiple markets and a strategic agency agreement in Australia.

RLF AgTech Ltd has closed FY2025 with a remarkable 74% increase in customer receipts and positive operating cash flow, underpinned by a comprehensive restructuring and renewed market momentum across Australia, China, and Asia.

Talius Group has reported a net profit of $0.37 million for Q2 2025, driven by a 6% increase in subscriptions and strategic partnerships that expand its market reach in aged care technology.

Lumos Diagnostics reported a 12% revenue increase for FY25 and inked a landmark US$317 million exclusive distribution deal for its FebriDx test, while advancing its FDA CLIA waiver application.

Lumos Diagnostics has locked in a A$5 million secured loan facility to support working capital as it advances toward FDA CLIA waiver for its FebriDx® test, complementing a landmark US distribution deal.